Tag: plasma therapy manufacturing
Australia’s CSL outlines USD 1.5B plan to boost US plasma therapy manufacturing capacity
Australian biotech firm CSL has announced plans to invest approximately USD 1.5 billion in the United States over the next five years, with the company stating the move is aimed at strengthening domestic manufacturing capacity for plasma-derived therapies.
Featured Article
What spending reveals about downstream consumer demand for manufactured goods
For manufacturers supplying consumer-facing markets, understanding demand conditions has become increasingly important in an environment shaped by cautious spending, rising costs and intense competition.
